Highlights Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
1.495 ^USD	-4.17%		-6.56%	-4.17%

05-23	Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024	CI
05-13	Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024	05-23	CI
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Top Premarket Gainers	05-06	MT
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated	04-25	CI
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers	04-16	MT
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors	04-16	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	15/03/23	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	15/03/23	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/03/23	CI
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer	06/01/23	CI
Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 Study of Ctx-009 in Biliary Tract Cancer at the 2023 ASCO GI Cancers Symposium	15/12/22	CI
Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy	01/12/22	CI
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
Compass Therapeutics Working With Merck to Conduct Clinical Trial of CTX-471	11/10/22	MT
Compass Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA (Pembrolizumab)	11/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Highlights

Filters